HPV vaccine success and the IP opportunities ahead

A milestone in cancer prevention

Recent data from England provides striking evidence of the real-world impact of the human papillomavirus (HPV) vaccination programme. A June 2026 study published in The Lancet reported that, among women aged 20–24 who had been vaccinated as adolescents, no cervical cancer deaths were recorded between 2020 and 2024, compared with an estimated 23 deaths expected in the absence of vaccination.

This finding translates to an effective ~100% reduction in cervical cancer mortality in this cohort under 30, representing one of the clearest examples to date of a vaccine-driven elimination effect for a cancer type. Earlier data had already demonstrated substantial impact on disease incidence. For example, vaccinated cohorts offered the vaccine at age 12–13 saw cervical cancer rates reduced by over 80%, alongside significant reductions in precancerous lesions.

These results prove that HPV vaccination can drastically reduce cervical cancer incidence and mortality in vaccinated cohorts.

Early, high coverage HPV vaccination: Success in the UK, Sweden and Denmark

The UK’s success is closely tied to the design and delivery of its HPV vaccination programme, introduced in 2008 and delivered primarily through schools to girls aged 12-13, has achieved high coverage rates (typically 80–90% pre-pandemic).

Several key factors underpin this success:

• Early vaccination timing: Immunisation prior to HPV exposure maximises effectiveness.
• High population coverage: Driving both direct protection and herd immunity.
• Integration with screening programmes: Reinforcing early detection and prevention.

Evidence from Scandinavia and broader Europe suggests that similar trends are emerging where vaccination uptake is high.

In Sweden and Denmark, both early adopters of HPV vaccination programmes, marked 80% declines in cervical cancer incidence among vaccinated young women have been observed, in contrast to countries with more limited or delayed roll-out.

Importantly, these results are only now emerging because the earliest vaccinated cohorts have only recently reached their 20s. The full long-term population-level impact is therefore still unfolding.

At an EU level, policy momentum is strong. The European Centre for Disease Prevention and Control (ECDC) highlights HPV vaccination as central to achieving the region’s goal of cervical cancer elimination (defined as <4 cases per 100,000 women), with a target of 90% vaccination coverage among girls by 2030.

Patent landscape and innovation trends

The remarkable clinical success of HPV vaccination has been underpinned by a strong and evolving patent landscape.

The near-elimination of cervical cancer deaths in vaccinated women under 30 marks a watershed in public health. For the first time, a common cancer is being effectively prevented at population scale through vaccination.

From an IP perspective, the HPV vaccine field illustrates a full innovation lifecycle.

Foundational platform patents enabled the first-generation of products

The first commercially successful HPV vaccines (e.g., Gardasil and Cervarix) were built on virus-like particle (VLP) technology, protected by broad foundational patents covering antigen design and assembly.  These products have dominated the market, with Gardasil variants estimated to account for a substantial majority of global sales.  

These early patent estates created significant commercial value, highlighting the importance of strong IP protection in supporting vaccine development.

Subsequent innovation focused on incremental improvements that optimise delivery and coverage including single-dose formulations, adjuvant systems (e.g. lipid nanoparticles, chitosan-based formulations), and valency expansion to cover additional HPV strains).  For example, recent patent applications describe single-dose HPV vaccine compositions incorporating nanoparticle-based adjuvants to achieve comparable or enhanced immune responses relative to multi-dose regimens.

New technology platforms are now opening further clinical possibilities.  Echoing broader vaccine innovation trends, HPV is now a target for mRNA-based vaccine platforms, with patent filings disclosing lipid nanoparticle formulations encoding multiple HPV antigens (e.g. E2, E6, E7 proteins).

Together, these developments show how the patent landscape has evolved from classic VLP based products to next generation dosing strategies and mRNA platforms, while continually expanding the space for novel, protectable solutions.

The unmet clinical need

Despite major advances in cervical cancer prevention, there remains a substantial unmet clinical need. Even in early adopter countries that began public HPV vaccination around 2008, the full cohort effect will take decades to mature: while incidence and mortality will fall markedly, unvaccinated and partially vaccinated generations will continue to drive a non negligible disease burden well into the 2050s–2060s and later elsewhere.

Therefore, there is a window for novel treatment approaches to address the unmet clinical needs that persist under current standard of care.

Standard of care has long relied on surgical excision and platinum based chemoradiation. Radical surgery has traditionally been the standard treatment for early-stage cervical cancer, even though it results in loss of fertility and long term urinary and sexual dysfunction (SEOM-GEICO). In turn, chemoradiation is associated with significant acute toxicity (haematologic, gastrointestinal) and chronic side effects such as peripheral neuropathy and fatigue.  However, across this treatment spectrum the overall burden remains high, creating a clear unmet need for novel approaches that maintain oncologic efficacy while reducing both acute and long term toxicity and morbidity.

As the average age of childbearing rises and demand for fertility-preserving options grows, the routine use of radical surgery in low-risk early-stage cervical cancer is increasingly being questioned, as shown in trials such as ConCerv. A key challenge is to identify which patients can safely undergo less radical, fertility-sparing surgery without compromising oncologic outcomes. Ideally, these conservative approaches would be supported by robust residual disease biomarkers, such as detection of circulating tumour HPV DNA as proposed in patents like CN119736395A. In this context, circulating tumour HPV DNA could be monitored to track treatment efficacy and enable early intervention before clinical recurrence, ensuring that reduced surgical intensity does not come at the expense of early detection and effective management of residual disease.

In recurrent and metastatic disease, immunotherapy has sought to exploit the presence of HPV related antigens in tumours, but with only limited success to date. PD L1–guided use of checkpoint inhibitors has shown a survival advantage for roughly 30–40% of patients. Encouragingly, a broader wave of immunotherapeutic strategies, including HPV targeted vaccines, adoptive cell therapies, and antibody–drug conjugates, is now moving through clinical development, offering real potential to extend these benefits to more patients and achieve more durable control of HPV positive cervical cancer.  

These emerging modalities also provide a fertile landscape for new composition of matter, combination therapy, and biomarker guided treatment patents that can capture clinically meaningful improvements in cervical cancer.

Looking ahead

HPV vaccination has become a standout success in cancer prevention, cutting cervical cancer incidence and even eliminating deaths in highly vaccinated young women in the England cohort. This represents an outcome built on decades of innovation and a substantial patent estate around VLP and next generation vaccine platforms. Extending high coverage vaccination to boys is now critical both to reinforce herd immunity and to prevent HPV driven oropharyngeal cancers.

Even with these gains, unvaccinated and partially vaccinated cohorts and patients with advanced or recurrent disease still face considerable risk, opening attractive IP niches for de escalated and fertility sparing surgery supported by minimal residual disease biomarkers, biomarker guided systemic therapies, and next generation immunotherapies and therapeutic HPV vaccines that can deliver more durable disease control with less toxicity.

Alice Mortiboy and David Gómez Jiménez are specialists in women’s health, vaccines, diagnostics, femtech and life sciences innovation within Potter Clarkson’s chemistry team. If you have questions about the issues discussed in this article and would like to continue the conversation, please contact us today.

‍